Maryland-based company seeking to leverage immune memory to battle cancer
COLUMBIA, Md., (November 24, 2025) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $500,000 Maryland Equity Investment Fund (MEIF) investment in VerImmune, Inc. The MEIF – which is housed under TEDCO’s Venture Funds – was created to increase private equity and venture capital in Maryland, generate financial returns, and foster economic growth.
VerImmune, Inc., located in Germantown, Md., is developing an innovative Virus-inspired Particle (ViP) platform delivery technology with the potential to treat multiple diseases. Their ViP program, VERI-101, features a mechanism known as Anti-tumor Immune Redirection (AIR), which aims to leverage a patient’s existing immune memory from past vaccines or infections to target and fight cancer. Through this approach, the company hopes to offer new treatments to those with limited options or who are resistant to current therapy options.
“With VERI-101, we set out to use our ViP platform to create a differentiated therapeutic approach for all cancer patients, especially those facing resistance to existing treatment options,” said Joshua Wang, Founder & CEO of VerImmune, Inc. “With TEDCO’s funding and support, we’re excited to continue advancing our research and development efforts, and move one step closer to bringing this treatment opportunity to patients in the clinic”
“We are excited about companies that could provide alternative solutions and treatments to patients, like VerImmune who is working to leverage the body’s existing immune memory to fight cancer and has the potential to impact much more than Maryland’s ecosystem,” said Katherine Hill Ritchie, senior director, Venture Funds, TEDCO. “We look forward to seeing VerImmune’s journey and hope the innovative spirit remains.”
TEDCO’s Venture Funds are one of the many investment opportunities TEDCO can provide to qualifying technology-based startups and small businesses throughout Maryland. For more information about eligibility, other resources and programs, or our investment funds, visit tedcomd.com.
“The innovative researchers and entrepreneurs help Maryland grow,” said TEDCO CEO Troy LeMaile-Stovall. “As the third-ranked biopharma cluster in the nation, it only makes sense that companies like VerImmune find a home here. We hope to welcome many other researchers and innovators to the area and look forward to remaining a valuable resource for continued growth.”